Humacyte (HUMA) Competitors $4.64 +1.18 (+34.10%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HUMA vs. APGE, IBRX, WVE, MIRM, AKRO, TARS, AMPH, IRON, CGON, and HRMYShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine CG Oncology Harmony Biosciences Apogee Therapeutics (NASDAQ:APGE) and Humacyte (NASDAQ:HUMA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Does the MarketBeat Community favor APGE or HUMA? Humacyte received 8 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 65.31% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformApogee TherapeuticsOutperform Votes24100.00% Underperform VotesNo VotesHumacyteOutperform Votes3265.31% Underperform Votes1734.69% Does the media favor APGE or HUMA? In the previous week, Humacyte had 29 more articles in the media than Apogee Therapeutics. MarketBeat recorded 44 mentions for Humacyte and 15 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.90 beat Humacyte's score of 0.17 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 11 Very Positive mention(s) 4 Positive mention(s) 24 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts prefer APGE or HUMA? Apogee Therapeutics currently has a consensus price target of $89.71, suggesting a potential upside of 88.04%. Humacyte has a consensus price target of $13.43, suggesting a potential upside of 189.41%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, APGE or HUMA? Apogee Therapeutics has higher earnings, but lower revenue than Humacyte. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$83.99M-$2.42-19.71Humacyte$1.57M371.97-$110.78M-$1.34-3.46 Which has more risk & volatility, APGE or HUMA? Apogee Therapeutics has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Do institutionals and insiders believe in APGE or HUMA? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 11.2% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is APGE or HUMA more profitable? Apogee Therapeutics' return on equity of -21.81% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -21.81% -20.94% Humacyte N/A -942.81%-93.82% SummaryApogee Therapeutics beats Humacyte on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$583.99M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-3.4646.7391.3417.19Price / Sales371.97411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book35.693.894.794.78Net Income-$110.78M-$42.21M$120.07M$225.60M7 Day Performance13.17%-2.14%-1.89%-1.24%1 Month Performance5.94%4.21%11.45%3.36%1 Year Performance65.12%18.40%30.61%16.58% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte3.3459 of 5 stars$4.64+34.1%$13.43+189.4%+69.3%$583.99M$1.57M-3.46150Analyst ForecastGap UpHigh Trading VolumeAPGEApogee Therapeutics2.5994 of 5 stars$46.76+5.1%$83.88+79.4%+92.5%$2.11BN/A-18.3991IBRXImmunityBio2.1332 of 5 stars$3.01+4.9%$17.38+477.2%-42.2%$2.10B$7.33M-3.36590Analyst ForecastWVEWave Life Sciences4.8841 of 5 stars$13.57+1.0%$22.22+63.8%+181.5%$2.07B$113.31M-12.11240MIRMMirum Pharmaceuticals4.0875 of 5 stars$42.51+0.2%$57.73+35.8%+34.8%$2.04B$307.03M-21.01140Positive NewsAKROAkero Therapeutics4.0824 of 5 stars$29.00+0.4%$46.83+61.5%+36.1%$2.02BN/A-7.7030Insider TradeTARSTarsus Pharmaceuticals0.3236 of 5 stars$51.39-2.1%$54.20+5.5%+164.4%$1.96B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.83-3.3%$60.33+47.8%-33.1%$1.96B$644.40M14.081,761IRONDisc Medicine3.4713 of 5 stars$65.45+0.9%$87.50+33.7%+13.2%$1.95BN/A-16.3078Insider TradeCGONCG Oncology2.1551 of 5 stars$28.49-0.9%$63.88+124.2%N/A$1.93B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7827 of 5 stars$32.72+1.0%$47.00+43.6%+7.0%$1.87B$681.88M15.35200Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies APGE Competitors IBRX Competitors WVE Competitors MIRM Competitors AKRO Competitors TARS Competitors AMPH Competitors IRON Competitors CGON Competitors HRMY Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HUMA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts